Maha Radhakrishnan, M.D.
Board Member
Candel Therapeutics, Inc. (CADL)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Maha Radhakrishnan, M.D.
Maha Radhakrishnan, M.D. is recorded as Board Member at Candel Therapeutics, Inc. (CADL). Candel Therapeutics, Inc. reported in an 8-K filed June 6, 2025 that Maha Radhakrishnan, M.D. was appointed member of the Board of Directors, effective June 4, 2025.
“On June 4, 2025, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) to ten (10) directors and unanimously appointed Maha Radhakrishnan, M.D., to fill the newly created vacancy on the Board, effective June 4, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-06-04–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Candel Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Charles Schoch CFO, Board Member
- Jason Amello CFO
- Diem Nguyen, Ph.D. Board Member
- Edward J. Benz Board Member
- Francesca Barone Board Member
- Gary Nabel Board Member
- Joseph Papa Board Member
- Maha Radhakrishnan Board Member
- Martine Zimmermann Board Member
- Nicoletta Loggia, Ph.D., R.Ph. Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.